首页 > 技术支持 > 文献速递

Rewiring immunity with in vivo CAR T cell engineering

Nature Cancer

Ex vivo engineered chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of certain hematologic malignancies, yet manufacturing complexities and limited patient accessibility constrain its impact. In vivo CAR T cell engineering seeks to overcome these limitations by generating CAR T cells directly within an individual. This Perspective examines the rapidly evolving field of in vivo CAR T cell generation in oncology, outlines principles of lymphocyte targeting, discusses pharmacology and biodistribution and assesses emerging safety issues. We conclude with a translational outlook, highlighting both the opportunities and the outstanding questions that will define the path to clinical implementation.

Related products

Catalog No. Product Name Description Target
MF815109 InVivo Plus Anti-Mouse CD8a/Lyt2 Antibody (2.43) InVivo Plus Anti-Mouse CD8a/Lyt2 Antibody (2.43) [2.43] (MF815109) is a rat monoclonal antibody detecting T-cell surface glycoprotein CD8 alpha chain in FCM, in vivo CD8+ T cell depletion, Western blot, Neutralization. Suitable for Mouse. Highlights ●Multi-Application — Validated across multiple applications. ●Flow Cytometry — Validated for flow cytometry applications. T-cell surface glycoprotein CD8 alpha chain, T-cell surface glycoprotein Lyt-2, CD8a, Cd8a, Lyt-2, Lyt2, cd8